Gain Therapeutics Inc. (GANX)
| Bid | 2.12 |
| Market Cap | 56.37M |
| Revenue (ttm) | 64.78K |
| Net Income (ttm) | -21.36M |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -1.99 |
| Forward PE | -2.65 |
| Analyst | Buy |
| Ask | 2.14 |
| Volume | 103,651 |
| Avg. Volume (20D) | 239,706 |
| Open | 1.99 |
| Previous Close | 1.90 |
| Day's Range | 1.99 - 2.15 |
| 52-Week Range | 0.89 - 5.19 |
| Beta | 0.15 |
About GANX
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing s...
Analyst Forecast
According to 4 analyst ratings, the average rating for GANX stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 252.94% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good ResultsGain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson's disease, with potential for substantial market impact and investor gains. The drug'...